Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
Portal Instrument's CEO, Dr. Patrick Anquetil, shares insights on reducing healthcare waste through reusable autoinjectors in a compelling OnDrug Delivery interview, "A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors."
We are thrilled to highlight a recent interview in OnDrug Delivery (Issue 171) featuring our CEO, Dr. Patrick Anquetil. Titled "A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors," the article tackles the significant environmental challenges and extensive waste generated by single-use autoinjectors in the self-injection market. Dr. Anquetil presents a compelling case for pivoting towards reusable electromechanical autoinjectors as a more sustainable and potentially cost-effective path forward. The discussion showcases Portal Instruments' solution, PRIME Nexus – a flexible, needle-based reusable platform – and explores broader insights into reducing waste, the benefits of connected reusable devices, and why sustainable innovation should ultimately lead to lower healthcare costs. The full article can be read in OnDrug Delivery.
May 9, 2022 - Gerresheimer AG, a leading provider of drug delivery systems, is expanding its portfolio of highly innovative platform technologies for drug delivery, today announcing an investment into US-based Portal Instruments.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
Please fill out the details below and we will get back to you shortly.